Investor’s Toolkit: Key Ratios for Assessing Tango Therapeutics Inc (TNGX)’s Performance

Kevin Freeman

In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.

Tango Therapeutics Inc (NASDAQ: TNGX) closed the day trading at $7.83 up 0.51% from the previous closing price of $7.79. In other words, the price has increased by $0.51 from its previous closing price. On the day, 5.46 million shares were traded. TNGX stock price reached its highest trading level at $8.25 during the session, while it also had its lowest trading level at $7.62.

Ratios:

For a better understanding of TNGX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.75 and its Current Ratio is at 4.75. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.24.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Piper Sandler on August 19, 2025, initiated with a Overweight rating and assigned the stock a target price of $11.

On July 17, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $19.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 23 ’25 when Third Rock Ventures IV, L.P. sold 477,401 shares for $10.15 per share. The transaction valued at 4,846,575 led to the insider holds 13,386,574 shares of the business.

Third Rock Ventures IV, L.P. bought 477,401 shares of TNGX for $3,594,830 on Oct 23 ’25. On Sep 25 ’25, another insider, Third Rock Ventures IV, L.P., who serves as the 10% Owner of the company, sold 500,000 shares for $8.02 each. As a result, the insider received 4,008,500 and left with 13,863,975 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNGX now has a Market Capitalization of 1035780480 and an Enterprise Value of 725390720. For the stock, the TTM Price-to-Sale (P/S) ratio is 43.18 while its Price-to-Book (P/B) ratio in mrq is 6.43. Its current Enterprise Value per Revenue stands at 29.856 whereas that against EBITDA is -4.686.

Stock Price History:

The Beta on a monthly basis for TNGX is 1.66, which has changed by 0.44066238 over the last 52 weeks, in comparison to a change of 0.20772064 over the same period for the S&P500. Over the past 52 weeks, TNGX has reached a high of $9.70, while it has fallen to a 52-week low of $1.03. The 50-Day Moving Average of the stock is 3.60%, while the 200-Day Moving Average is calculated to be 77.61%.

Shares Statistics:

Over the past 3-months, TNGX traded about 2.67M shares per day on average, while over the past 10 days, TNGX traded about 5954230 shares per day. A total of 110.87M shares are outstanding, with a floating share count of 76.48M. Insiders hold about 42.18% of the company’s shares, while institutions hold 61.64% stake in the company. Shares short for TNGX as of 1760486400 were 36347898 with a Short Ratio of 13.61, compared to 1757894400 on 26798166. Therefore, it implies a Short% of Shares Outstanding of 36347898 and a Short% of Float of 39.200002.

Earnings Estimates

. The current assessment of Tango Therapeutics Inc (TNGX) involves the perspectives of 8.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.32, with high estimates of -$0.25 and low estimates of -$0.39.

Analysts are recommending an EPS of between -$0.9 and -$1.49 for the fiscal current year, implying an average EPS of -$1.07. EPS for the following year is -$1.31, with 7.0 analysts recommending between -$1.1 and -$1.51.

Revenue Estimates

8 analysts predict $41.24M in revenue for. The current quarter. It ranges from a high estimate of $53.81M to a low estimate of $3.18M. As of. The current estimate, Tango Therapeutics Inc’s year-ago sales were $11.61M

A total of 8 analysts have provided revenue estimates for TNGX’s current fiscal year. The highest revenue estimate was $62.4M, while the lowest revenue estimate was $14.94M, resulting in an average revenue estimate of $53.92M. In the same quarter a year ago, actual revenue was $42.07M

DwinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.